Boundless Bio to Participate in the Needham Virtual Healthcare Conference
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology, has announced its participation in the upcoming Needham Virtual Healthcare Conference.
The company's President and CEO, Zachary Hornby, will deliver a presentation on Thursday, April 10, 2025, at 1:30 p.m. ET. Investors and interested parties can access both the live and archived webcasts of the presentation through the 'Events & Presentations' section of Boundless Bio's website or directly via the provided webcast link.
Boundless Bio (Nasdaq: BOLD), un'azienda oncologica in fase clinica focalizzata sulla biologia del DNA estrachromosomico (ecDNA), ha annunciato la sua partecipazione alla prossima Conferenza Virtuale sulla Salute di Needham.
Il Presidente e CEO dell'azienda, Zachary Hornby, presenterà un intervento giovedì 10 aprile 2025, alle 13:30 ET. Gli investitori e le parti interessate possono accedere sia alla diretta che alle registrazioni della presentazione attraverso la sezione 'Eventi e Presentazioni' del sito web di Boundless Bio o direttamente tramite il link fornito per la trasmissione.
Boundless Bio (Nasdaq: BOLD), una empresa de oncología en etapa clínica centrada en la biología del ADN extracromosómico (ecDNA), ha anunciado su participación en la próxima Conferencia Virtual de Salud de Needham.
El presidente y CEO de la empresa, Zachary Hornby, realizará una presentación el jueves 10 de abril de 2025, a la 1:30 p.m. ET. Los inversores y partes interesadas pueden acceder tanto a la transmisión en vivo como a las grabaciones de la presentación a través de la sección 'Eventos y Presentaciones' del sitio web de Boundless Bio o directamente a través del enlace de transmisión proporcionado.
Boundless Bio (Nasdaq: BOLD)는 엑스트라크로모좀 DNA(ecDNA) 생물학에 중점을 둔 임상 단계의 종양학 회사로, 다가오는 니드햄 가상 헬스케어 컨퍼런스에 참여한다고 발표했습니다.
회사의 사장 겸 CEO인 Zachary Hornby는 2025년 4월 10일 목요일, 오후 1시 30분 ET에 발표를 진행할 예정입니다. 투자자 및 관심 있는 당사자는 Boundless Bio 웹사이트의 '이벤트 및 발표' 섹션을 통해 발표의 실시간 및 녹화된 웹캐스트에 접근할 수 있으며, 제공된 웹캐스트 링크를 통해 직접 접근할 수 있습니다.
Boundless Bio (Nasdaq: BOLD), une entreprise d'oncologie en phase clinique axée sur la biologie de l'ADN extracromosomique (ecDNA), a annoncé sa participation à la prochaine Conférence Virtuelle sur la Santé de Needham.
Le président et PDG de l'entreprise, Zachary Hornby, fera une présentation le jeudi 10 avril 2025, à 13h30 ET. Les investisseurs et les parties intéressées peuvent accéder à la fois aux diffusions en direct et aux enregistrements de la présentation via la section 'Événements & Présentations' du site Web de Boundless Bio ou directement via le lien de diffusion fourni.
Boundless Bio (Nasdaq: BOLD), ein klinisches Onkologieunternehmen, das sich auf die Biologie von extrachromosomalem DNA (ecDNA) konzentriert, hat seine Teilnahme an der bevorstehenden Needham Virtuellen Gesundheitskonferenz bekannt gegeben.
Der Präsident und CEO des Unternehmens, Zachary Hornby, wird am Donnerstag, den 10. April 2025, um 13:30 Uhr ET eine Präsentation halten. Investoren und Interessierte können sowohl auf die Live- als auch auf die archivierten Webcasts der Präsentation über den Bereich 'Veranstaltungen & Präsentationen' auf der Website von Boundless Bio oder direkt über den bereitgestellten Webcast-Link zugreifen.
- None.
- None.
SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in Needham’s Virtual Healthcare Conference.
A company presentation is scheduled for Thursday, April 10, 2025, at 1:30 p.m. ET. A live and archived webcast of the session will be accessible under “Events & Presentations” in the Investors section of Boundless Bio’s website and can be accessed via this link: https://wsw.com/webcast/needham146/bold/2230221.
About Boundless Bio
Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics to address the significant unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in 14 to
Contacts:
Ben Flaum, Boundless Bio
bflaum@boundlessbio.com
Investors
THRUST Strategic Communications
Renee Leck
renee@thrustsc.com
FAQ
When is Boundless Bio (BOLD) presenting at the Needham Virtual Healthcare Conference?
How can investors access Boundless Bio's (BOLD) Needham Conference presentation?
What is Boundless Bio's (BOLD) main research focus?
Who will represent Boundless Bio (BOLD) at the Needham Healthcare Conference?
